Rocky Mountain MS Clinic and Research Group Publications and Presentations

Journal of Neurology

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Gobel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz – Fejfar A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Halva J, Kumpfel T, Meinl I, Niessen K, Goelz S, Kleinschni

Sep 30, 2013, L-Section is a Possible Biomarker for Individual PML Risk in Natalizumab-treated MS Patients

Biologics: Targets and Therapy

Damal K, Stoker E, Foley JF

Sep 30, 2013, Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action

Health and quality of life outcomes

Stephenson JJ, Kern DM, Agarwal SS

Oct 23, 2012, Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study


Foley JF

May 30, 2012, Natalizumab Kinetics and Dose Extension: Defining the Therapeutic Envelope